Pharmacological treatment of obesity

Article Sidebar

PDF (Spanish)
Published: 2009-06-10
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v29i1.1058

Main Article Content

Susana Gutt
Sección Nutrición. Servicio de Clínica Médica. Hospital Italiano de Buenos Aires, Argentina

Abstract

.

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 29 No. 1 (2009): Revista del Hospital Italiano de Buenos Aires

Section

Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
Gutt S. Pharmacological treatment of obesity. Rev Hosp Ital B.Aires [Internet]. 2009 Jun. 10 [cited 2026 Apr. 27];29(1):10-6. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/1058

References

salas-salvadó J, rubio Ma, Barbany M, et al. conferencia de consenso – consenso seedo 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med clin (Barc). 2007;128(5):184-96. DOI: https://doi.org/10.1016/S0025-7753(07)72531-9

snow v, Barry P, Fittermann, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the american college of Physicians. ann intern Med. 2005;142(7):525-31. DOI: https://doi.org/10.7326/0003-4819-142-7-200504050-00011

Bray Ga, ryan dH. drug treatment of the overweight patient. Gastroenterology. 2007;132(6):2239-2352. DOI: https://doi.org/10.1053/j.gastro.2007.03.053

Pena M, Bacallao J. la obesidad en la pobreza: un problema emergente en las américas. revista Futuros [internet]. 2005 [citado 02/02/2009];3(10). disponible en: http://www.revistafuturos.info/futuros_10/obesidad1.htm.

sjöström l, rissanen a, andersen t, et al. randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. european Multicentre orlistat study Group. lancet. 1998;352(9123):167-72. DOI: https://doi.org/10.1016/S0140-6736(97)11509-4

national institutes of Health. national Heart, lung, and Blood institute. north american association for the study of obesity. the practical guide identification, evaluation, and treatment of overweight and obesity in adults [internet]. [Bethesda]: u.s. department of Health and Human services. national institutes of Health; oct. 2000. (niH Publications; 00-4084) [citado: 02/02/2009]. disponible en: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_b.pdf

snow v, Barry P, Fittermann, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the american college of Physicians. ann intern Med. 2005;142(7):525-31. DOI: https://doi.org/10.7326/0003-4819-142-7-200504050-00011

u.s. Food and drug administration. center for drug evaluation and research. drug for approvals for november 1997 [internet]. [citado: 02/04/2002]. disponible en: http://www.fda.gov/cder/da/da1197.htm y u. s. national library of Medicine. Medline Plus Health information. drugs & supplements. sibutramine [internet]. Bethesda: national library of Medicine; 2009. [citado: 02/04/2009]. disponible en: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601110.html

Pi-sunyer FX, aronne lJ, Heshmati HM, et al. study Group. effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: rio-north america: a randomized controlled trial. JaMa. 2006;295(7):761-75. errata en: JaMa. 2006;295(11):1252. DOI: https://doi.org/10.1001/jama.295.7.761

Mcneely W, Goa Kl. sibutramine. a review of its contribution to the management of obesity. drugs. 1998;56(6):1093-124. DOI: https://doi.org/10.2165/00003495-199856060-00019

Yanovski sZ, Yanovski Ja. obesity. n engl J Med. 2002;346(8):591-602. DOI: https://doi.org/10.1056/NEJMra012586

Padwal rs, Majumdar sr drug treatments for obesity: orlistat, sibutramine, and rimonabant. lancet. 2007;369(9555):71-7. DOI: https://doi.org/10.1016/S0140-6736(07)60033-6

Gadde KM, Franciscy dM, Wagner Hr 2nd, et al. Zonisamide for weightloss in obese adults: a randomized controlled trial. JaMa. 2003;289(14):1820-5 DOI: https://doi.org/10.1001/jama.289.14.1820

Weigle ds. Pharmacological therapy of obesity: past, present, and future. J clin endocrinol Metab. 2003;88(6):2462-9. DOI: https://doi.org/10.1210/jc.2003-030151

van Gaal lF, rissanen aM, scheen aJ, et al. effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the rio-europe study. lancet. 2005;365(9468):1389-97. errata en: lancet. 2005;366(9483):370 DOI: https://doi.org/10.1016/S0140-6736(05)66374-X

tonstad s. rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. nutr Metab cardiovasc dis. 2006;16(2):156-62 DOI: https://doi.org/10.1016/j.numecd.2005.10.011